The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone

The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy which leads to a median survival of 6-15 months. Survival beyond 3 years is rare. For selected groups of patients with limited MGC, retrospective studies have shown improved overall survival following gastrectomy and m...

Full description

Saved in:

Bibliographic Details
Published in:	Current controlled trials in cardiovascular medicine Vol. 10; no. 1; p. 121
Main Authors:	Kerkar, Sid P, Kemp, Clinton D, Duffy, Austin, Kammula, Udai S, Schrump, David S, Kwong, King F, Quezado, Martha, Goldspiel, Barry R, Venkatesan, Aradhana, Berger, Ann, Walker, Melissa, Toomey, Mary Ann, Steinberg, Seth M, Giaccone, Guiseppe, Rosenberg, Steven A, Avital, Itzhak
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 23-12-2009 BioMed Central BMC
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - analogs & derivatives Camptothecin - therapeutic use Cancer Cancer therapies Care and treatment Chemotherapy Combined Modality Therapy Fluorouracil - therapeutic use Gastrectomy Gastric cancer Gastrointestinal surgery Hepatectomy Humans Hyperthermia, Induced - methods Laparoscopy Leucovorin - therapeutic use Liver Metastasis Methods Organoplatinum Compounds - therapeutic use Patients Peritoneum - surgery Pneumonectomy Stomach cancer Stomach Neoplasms - drug therapy Stomach Neoplasms - secondary Stomach Neoplasms - surgery Study protocol Survival Rate United States United States > US Maryland
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!